neoag.ai — daily neoantigen × AI signal

Neoantigen vaccines diversify beyond peptides into mRNA and nanovaccines

Today’s brief highlights the diversification of neoantigen vaccine platforms beyond synthetic peptides, with new entries in mRNA, nanovaccine, and dendritic cell modalities targeting adjuvant settings in colorectal, liver, and pancreatic cancers.trial trial trial trial

On the methodological front, researchers introduce QCAI to interpret cross-attention mechanisms in transformer models for TCR-pMHC binding, addressing a key interpretability gap in AI-driven epitope prediction.arXiv

Clinical3 days agoNew

Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies

The National Cancer Institute is recruiting for a Phase 1 study of neoepitope-specific T cells for patients with nine types of blood cancers, including those with TP53 or RAS mutations. The protocol involves autologous T-cell isolation and expansion to target patient-specific neoepitopes, addressing the challenge of treating hard-to-treat hematologic malignancies.

clinicaltrials · 3 days ago · National Cancer Institute (NCI)

Also new today05

AI / Methods3 days agoNew

CaliPPer: quantifying, predicting and improving AI model performance for binding prediction

Researchers present CaliPPer, a post-hoc framework that quantifies and improves AI model performance for binding prediction using distance-aware Bayesian recalibration. Applied to TCR and BCR models, CaliPPer significantly reduces mean absolute errors in AUROC/AP/F1 predictions and increases true discovery rates on unseen epitopes by providing per-sample confidence scores.

arxiv · 3 days ago · Jian-Qing Zheng, Hantao Lou, Zinan Yin, Sam Farrar, Yuze Zhou, Elie Antoun, Xiangxi Wang,

Clinicallast weekNew

Intermediate-size IND for Treatment of Patients With Advanced Cancer Using T Cells Engineered to Express TCR Targeting Mutant KRAS

Providence Health & Services is managing an intermediate-size expanded access program for T-cells engineered with TCRs targeting the KRAS-G12D neoantigen in advanced pancreatic and colorectal cancers. The protocol involves autologous T-cell transduction with GMP-grade retroviral vectors followed by lymphodepletion, offering a potential treatment avenue for patients with limited options harboring this specific mutation.

clinicaltrials · last week · Providence Health & Services

Clinicallast weekNew

Expanded Access to PCNAT-01 for Patients With Resected Pancreatic Ductal Adenocarcinoma Following Surgical Resection and Adjuvant Therapy

Anda Biopharmaceutical has launched an expanded access program for PCNAT-01, a personalized tumor neoantigen peptide vaccine, targeting patients with resected pancreatic ductal adenocarcinoma (PDAC) following adjuvant therapy. This initiative aims to reduce recurrence risk in disease-free patients who cannot participate in ongoing trials, marking a strategic move to broaden patient access outside standard clinical development pathways.

clinicaltrials · last week · Anda Biopharmaceutical Development (Shenzhen) Co., Ltd.

Clinicallast weekNew

A Personalized Neoantigen Cancer Vaccine in Treatment Naïve, Asymptomatic Patients With IGHV Unmutated CLL.

Dana-Farber Cancer Institute is recruiting for a Phase 1 study of a personalized neoantigen vaccine in treatment-naïve, asymptomatic patients with IGHV unmutated chronic lymphocytic leukemia (CLL). The intervention combines the vaccine with Poly-ICLC, cyclophosphamide, and pembrolizumab to evaluate safety and immunogenicity in this specific CLL subtype.

clinicaltrials · last week · Dana-Farber Cancer Institute

Clinicallast weekNew

Personalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Neoadjuvant Triple-negative Breast Cancer

NEC Bio B.V. is conducting a Phase I/II trial of NECVAX-NEO1, a personalized neoantigen-targeting vaccine in neoadjuvant triple-negative breast cancer. The study evaluates the vaccine's combination with standard-of-care chemotherapy and anti-PD-1 therapy, with potential post-surgical extension to assess immune response and clinical outcomes in early-stage disease.

clinicaltrials · last week · NEC Bio B.V